NEW YORK (GenomeWeb News) – Medicyte and Reinnervate today announced a collaboration to combine their technologies, bringing a next generation of cell-based assays to the biopharma and academic research markets.

The partnership brings together Medicyte's upcyte technology and Reinnervate's Alvetex Scaffold technologies. Upcyte are genetically engineered "upregulated" primary cells, and according to Medicyte, data suggests that upcyte hepatocytes combine the benefits of quantity — up to 2,000 vials per donor can be generated — and the quality of primary hepatocytes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene regulation changes linked to human brain evolution, and more.

The New York Stem Cell Foundation's Initiative on Women in Science and Engineering working group presents seven strategies to promote gender equality in the sciences.

Researchers link a genetic variation to the ability to quickly process arsenic in people living in the Andes Mountains.

A small portion of pregnant women who've undergone non-invasive prenatal testing have found out from the test that they have cancer.